Nuveen
SGMT icon

Nuveen’s Sagimet Biosciences SGMT Stock Holding History

Nuveen’s Portfolio SGMT Stock Details SGMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.09M Buy
+140,637
New +$956K ﹤0.01% 2899
2024
Q2 		– Sell
-91,655
Closed -$497K – 3406
2024
Q1 		$497K Buy
+91,655
New +$658K ﹤0.01% 2977

Other funds holding SGMT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $962M AUM 524.64% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return

Nuveen's SGMT Position: Q2 2026 in Review

Nuveen opened a new position in Sagimet Biosciences (SGMT) in Q2 2026: 140,637 shares worth $1.09M. The stake represents ﹤0.01% of the portfolio and ranks #2899 among its holdings. This is a return to the name: Nuveen previously reported a position in SGMT as recently as Q1 2024.

Nuveen first reported a position in SGMT in Q1 2024 and has held it in 2 quarters since. 122 funds tracked by Wall St. Rank hold SGMT as of Q2 2026.

  • Nuveen held 140,637 shares of Sagimet Biosciences worth $1.09M as of Q2 2026.
  • Sagimet Biosciences was a new Nuveen position in Q2 2026.
  • Sagimet Biosciences made up ﹤0.01% of Nuveen's portfolio in Q2 2026, its #2899 holding.
  • Nuveen first reported a position in Sagimet Biosciences in Q1 2024 and has held it in 2 quarters since.
  • 122 funds tracked by Wall St. Rank held Sagimet Biosciences as of Q2 2026.

Based on Nuveen's 13F filing for Q2 2026, filed 11 Aug 2026.